Categories: Clinical TrialNews

ObvioHealth Introduces ObvioGo 2.2: Transforming Study Management with AI-Driven Innovation

AI-Driven Enhancements in ObvioGo 2.2 Redefine Efficiency, Compliance, and Innovation in Clinical Trial Management 

NEW YORK, Jan. 14, 2025 /PRNewswire/ — ObvioHealth, a global leader in digital clinical trial solutions, today announced the release of ObvioGo 2.2, the latest version of its innovative platform. This release introduces advanced functionalities designed to streamline study management by leveraging artificial intelligence, enhanced interoperability, and a no-code environment for seamless integration with existing systems and AI models.

ObvioGo 2.2 offers powerful new workflow and task management tools to streamline and enhance trial operations. With real-time compliance tracking and reporting, study teams can proactively identify and address adverse events (AEs), protocol deviations, and compliance risks as they arise, simplifying study management and improving overall efficiency. ObvioGo’s unified platform, now integrating real-time tracking, reporting, and a centralized data repository, unlocks new and novel AI capabilities. It enables seamless integration with existing AI models and the deployment of agentic functionalities, revolutionizing clinical trial efficiency, compliance, and safety.

“ObvioGo 2.2 represents a fundamental shift in clinical trial management, setting a new standard for efficiency and innovation” said Ivan Jarry, CEO of ObvioHealth. “By integrating AI-ready capabilities and seamless connectivity, we are redefining operational efficiency and ensuring data and tasks are organized and accessible for study teams. This release sets a new standard for delivering smarter, faster, and more reliable clinical research outcomes.”

These enhancements simplify the study manager’s role by organizing tasks and data in real-time, paving the way for more efficient and effective trial management. ObvioGo 2.2 underscores ObvioHealth’s commitment to innovation, positioning the company as a leader in AI-driven clinical trial solutions. With its robust capabilities, the platform meets the growing demand for efficient, scalable, and tech-enabled research solutions, delivering significant value to sponsors and advancing the future of clinical research.

About ObvioHealth

ObvioHealth is a global leader in digital clinical trial solutions, delivering smarter, faster, and more cost-effective trials through its innovative ObvioGo platform. By integrating advanced technology with patient-centric design, ObvioHealth ensures high-quality data collection and transformative outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/obviohealth-introduces-obviogo-2-2-transforming-study-management-with-ai-driven-innovation-302349730.html

SOURCE ObvioHealth

Staff

Recent Posts

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - January 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

54 minutes ago

Rancho Biosciences and ONTOFORCE Collaborate to Leverage High Quality Data for Target Identification

SAN DIEGO, CALIFORNIA / ACCESSWIRE / January 15, 2025 / Rancho BioSciences, the premier tech-enabled…

2 hours ago

Unlocking the Power of High-Dimensional Simulations with STDE

SINGAPORE, Jan. 15, 2025 /PRNewswire/ -- In a world increasingly driven by artificial intelligence and complex…

8 hours ago

Taiwan’s Startup Hub in Silicon Valley Bridges U.S.-Taiwan Innovation Collaboration and Promotes Taiwan’s Startups to the World

PALO ALTO, Calif., Jan. 14, 2025 /PRNewswire/ -- A news report from Business Next Media…

8 hours ago

2025 Sunhak Peace Prize: Honoring Global Leaders in Peace innovation

SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- The Sunhak Peace Prize Committee, chaired by José…

8 hours ago